Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) Hits New 1-Year High – Should You Buy?

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX)’s stock price hit a new 52-week high during mid-day trading on Saturday . The stock traded as high as $20.00 and last traded at $19.50, with a volume of 39684 shares. The stock had previously closed at $17.41.

Analyst Ratings Changes

A number of brokerages have weighed in on TLX. UBS Group lifted their target price on Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a research report on Monday, January 27th. William Blair upgraded Telix Pharmaceuticals Limited American Depositary Shares to a “strong-buy” rating in a report on Tuesday, November 19th.

Telix Pharmaceuticals Limited American Depositary Shares Trading Up 12.0 %

The firm has a 50-day moving average of $16.67.

About Telix Pharmaceuticals Limited American Depositary Shares

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.